David R. Bauer

Davis Polk advised the representatives of the underwriters in connection with the $175 million public offering by Cellectis S.A. of 5,646,000 American Depositary Shares, each representing…

Davis Polk advised the joint book-running managers in connection with the $80 million public offering of common stock of Dova Pharmaceuticals, Inc. The common stock is listed on the NASDAQ…

Davis Polk advised the initial purchasers on a Rule 144A offering by Avadel Finance Cayman Limited, a wholly owned subsidiary of Avadel Pharmaceuticals plc, of $143.7 million aggregate…

Davis Polk is advising Roche on its $1.9 billion acquisition of Flatiron Health, Inc. The transaction, which is expected to close in the first half of 2018, is subject to customary closing…

Davis Polk advised the joint book-running managers in connection with the $133.7 million initial public offering of common stock of Solid Biosciences Inc. The common stock is listed on the…

Davis Polk is advising The Ferrero Group on its $2.8 billion acquisition of Nestlé’s U.S. confectionary business. The transaction, which is subject to customary closing conditions and…

Davis Polk advised the underwriters in connection with an initial public offering of 15,972,221 shares of common stock of Denali Therapeutics Inc., including shares sold pursuant to the…

Davis Polk advised the sole book-running manager in connection with the $50 million follow-on offering of 1,970,000 shares of common stock of Editas Medicine, Inc. The common…

Davis Polk advised InflaRx N.V. on its $100 million initial public offering of 6,667,000 of its common shares. In addition, InflaRx has granted the underwriters a 30-day option to purchase…

Davis Polk advised the underwriters in connection with an initial public offering of 5,333,333 shares of common stock of Allena Pharmaceuticals, Inc., at $14.00 per share, for total gross…